Skip to main content

Table 3 Univariate and multivariate associations between patient characteristics and survival

From: Treatment-duration is related to changes in peripheral lymphocyte counts during definitive radiotherapy for unresectable stage III NSCLC

Characteristic

Progression-free survival

Overall survival

HR (95% CI)

P value

HR (95% CI)

P value

Univariate associations

 Sex (female vs male)

0.752 (0.274–2.062)

0.579

0.357 (0.049–2.593)

0.308

 Age (<  65 years vs ≥ 65 years)

0.690 (0.430–1.108)

0.125

0.880 (0.492–1.572)

0.880

 ECOG performance status (0–1 vs 2)

1.930 (1.189–3.132)

0.008

1.152 (0.608–2.184)

0.665

 Smoker (No vs others)

1.164 (0.662–2.045)

0.598

0.995 (0.496–1.997)

0.989

 Histology (Squamous carcinoma vs others)

1.035 (0.653–1.642)

0.882

0.673 (0.366–1.238)

0.202

 Stage

  IIIA vs IIIB

1.273 (0.655–2.476)

0.477

1.520 (0.624–3.705)

0.357

  IIIA vs IIIC

0.914 (0.496–1.683)

0.773

1.056 (0.458–2.438)

0.898

 Chemotherapy (concurrent vs sequent)

1.529 (0.905–2.584)

0.113

2.350 (1.185–4.663)

0.014

 GTV (cm3)

1.002 (1.000–1.004)

0.014

1.004 (1.002–1.006)

<  0.001

 PTV (cm3)

1.002 (1.001–1.003)

0.002

1.002 (1.001–1.004)

<  0.001

 BED (Gy)

1.033 (0.969–1.101)

0.323

1.076 (0.994–1.164)

0.069

 Baseline TLCs (cells/μL)

1.000 (0.999–1.000)

0.437

1.000 (0.999–1.001)

0.699

 Pre-RT TLCs (cells/μL)

1.000 (0.999–1.000)

0.197

1.000 (0.999–1.000)

0.603

 SL (Yes vs No)

0.524 (0.331–0.831)

0.006

0.460 (0.255–0.831)

0.010

 TLCs nadir (cells/μL)

0.999 (0.998–1.000)

0.012

0.999 (0.997–1.000)

0.013

 OTT (LTRT vs STRT)

0.671 (0.386–1.167)

0.158

0.519 (0.249–1.081)

0.080

 IMRT (vs 3DCRT)

1.489 (0.881–2.517)

0.137

1.629 (0.850–3.122)

0.141

 HT (vs 3DCRT)

1.072 (0.621–1.849)

0.803

0.987 (0.474–2.053)

0.972

Multivariate associations

 ECOG performance status (0–1 vs 2)

1.720 (1.052–2.811)

0.031

N/A

N/A

 PTV (cm3)

1.002 (1000–1.003)

0.006

1.002 (1.001–1.004)

< 0.001

 SL (Yes vs No)

0.544 (0.343–0.863)

0.010

0.463 (0.256–0.837)

0.011

  1. Abbreviations: HR Hazard ratio, CI confidence interval, ECOG Eastern Cooperative Oncology Group, GTV gross tumor volume, PTV planning target volume, BED biological effective dose, TLCs total peripheral lymphocyte counts, RT radiotherapy, SL severe lymphopenia, OTT overall treatment time, Heart V5 the percentage of total heart volume receiving at least 5 Gy, LTRT long-term radiotherapy, STRT short-term radiotherapy, 3DCRT 3D conformal radiotherapy, IMRT Intensity modulated radiotherapy, HT Helical Tomotherapy, N/A not available
  2. Note: Multivariate analysis includes sex, age, ECOG, and variables with a P values of ≤0.2 on univariate analysis
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us